The price of the CD27-CD70 costimulatory axis: You can't have it all

Journal of Experimental Medicine

Volumn 203, Issue 11, 2006, Pages 2405-2408

  Nolte, Martijn A ^a   Van Lier, René A W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD70 ANTIGEN; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMORAL IMMUNITY; IMMUNITY; LEISHMANIA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY T LYMPHOCYTE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD27; ANTIGENS, CD70; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-LYMPHOCYTES;

EID: 33750522042     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20061840     Document Type: Review

References (30)

1. Matter, M., B. Odermatt, H. Yagita, J.M. Nuoffer, and A.F. Ochsenbein. 2006. Elimination of chronic viral infection by blocking CD27 signaling. J. Exp. Med. 203:2145-2155.
2. Hendriks, J., L.A. Gravestein, K. Tesselaar, R.A. van Lier, T.N. Schumacher, and J. Borst. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1:433-440.
3. + T cell formation. J. Exp. Med. 199:1595-1605.
4. Matter, M., S. Mumprecht, D.D. Pinschewer, V. Pavelic, H. Yagita, S. Krautwald, J. Borst, and A.F. Ochsenbein. 2005. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. Eur. J. Immunol. 35:3229-3239.
5. Arens, R., K. Tesselaar, P.A. Baars, G.M. van Schijndel, J. Hendriks, S.T. Pals, P. Krimpenfort, J. Borst, M.H. van Oers, and R.A. van Lier. 2001. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity. 15:801-812.
6. Nolte, M.A., R. Arens, M. Kraus, M.H. van Oers, G. Kraal, R.A. van Lier, and R.E. Mebius. 2004. B cells are crucial for both development and maintenance of the splenic marginal zone. J. Immunol. 172:3620-3627.
7. Muller, S., L. Hunziker, S. Enzler, M. Buhler-Jungo, J.P. Di Santo, R.M. Zinkernagel, and C. Mueller. 2002. Role of an intact splenic microarchitecture in early lymphocytic choriomeningitis virus production. J. Virol. 76:2375-2383.
8. Seiler, P., P. Aichele, B. Odermatt, H. Hengartner, R.M. Zinkernagel, and R.A. Schwendener. 1997. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 27:2626-2633.
9. Fehr, T., C. Lopez-Macias, B. Odermatt, R.M. Torres, D.B. Schubart, T.L. O'Keefe, P. Matthias, H. Hengartner, and R.M. Zinkernagel. 2000. Correlation of anti-viral B cell responses and splenic morphology with expression of B cell-specific molecules. Int. Immunol. 12:1275-1284.
10. Mebius, R.E., M.A. Nolte, and G. Kraal. 2004. Development and function of the splenic marginal zone. Crit. Rev. Immunol. 24:449-464.
11. Ochsenbein, A.F., T. Fehr, C. Lutz, M. Suter, F. Brombacher, H. Hengartner, and R.M. Zinkernagel. 1999. Control of early viral and bacterial distribution and disease by natural antibodies. Science. 286:2156-2159.
12. Seiler, P., M.A. Brundler, C. Zimmermann, D. Weibel, M. Bruns, H. Hengartner, and R.M. Zinkernagel. 1998. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J. Exp. Med. 187:649-654.
13. Zinkernagel, R.M., A. LaMarre, A. Ciurea, L. Hunziker, A.F. Ochsenbein, K.D. McCoy, T. Fehr, M.F. Bachmann, U. Kalinke, and H. Hengartner. 2001. Neutralizing antiviral antibody responses. Adv. Immunol. 79:1-53.
14. Odermatt, B., M. Eppler, T.P. Leist, H. Hengartner, and R.M. Zinkernagel. 1991. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc. Natl. Acad. Sci. USA. 88:8252-8256.
15. Karlsson, M.C., R. Guinamard, S. Bolland, M. Sankala, R.M. Steinman, and J.V. Ravetch. 2003. Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J. Exp. Med. 198:333-340.
16. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3:609-620.
17. Zhu, G., D.B. Flies, K. Tamada, Y. Sun, M. Rodriguez, Y.X. Fu, and L. Chen. 2001. Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha)-transgenic mice. J. Immunol. 167:2671-2676.
18. Trinchieri, G. 1997. Function and clinical use of interleukin-12. Curr. Opin. Hematol. 4:59-66.
19. Ato, M., H. Nakano, T. Kakiuchi, and P.M. Kaye. 2004. Localization of marginal zone macrophages is regulated by C-C chemokine ligands 21/19. J. Immunol. 173:4815-4820.
20. Engwerda, C.R., M. Ato, S.E. Cotterell, T.L. Mynott, A. Tschannerl, P.M. Gorak-Stolinska, and P.M. Kaye. 2002. A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am. J. Pathol. 161:429-437.
21. Akiba, H., Y. Miyahira, M. Atsuta, K. Takeda, C. Nohara, T. Futagawa, H. Matsuda, T. Aoki, H. Yagita, and K. Okumura. 2000. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191:375-380.
22. Andrade, T.M., E.M. Carvalho, and H. Rocha. 1990. Bacterial infections in patients with visceral leishmaniasis. J. Infect. Dis. 162:1354-1359.
23. Koopman,G., P.C. Wever, M.D. Ramkema, F. Bellot, P. Reiss, R.M. Keehnen, I.J. Ten Berge, and S.T. Pals. 1997. Expression of granzyme B by cytotoxic T lymphocytes in the lymph nodes of HIV-infected patients. AIDS Res. Hum. Retroviruses. 13:227-233.
24. Koopman, G., and S.T. Pals. 1992. Cellular interactions in the germinal center: role of adhesion receptors and significance for the pathogenesis of AIDS and malignant lymphoma. Immunol. Rev. 126:21-45.
25. Wilkins, B.S., Z. Davis, S.B. Lucas, G. Delsol, and D.B. Jones. 2003. Splenic marginal zone atrophy and progressive CD8+ T-cell lymphocytosis in HIV infection: a study of adult post-mortem spleens from Cote d'Ivoire. Histopathology. 42:173-185.
26. Beaumont, T., S. Broersen, A. van Neunen, H.G. Huisman, A.M. de Roda Husman, J.L. Heeney, and H. Schuitemaker. 2000. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J. Virol. 74:7699-7707.
27. Hazenberg,M.D.,D.Hamann,H.Schuitemaker, and F. Miedema. 2000. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat. Immunol. 1:285-289.
28. Gougeon, M.L., H. Lecoeur, F. Boudet, E. Ledru, S. Marzabal, S. Boullier, R. Roue, S. Nagata, and J. Heeney. 1997. Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. J. Immunol. 158:2964-2976.
29. Wolthers, K.C., S.A. Otto, S.M. Lens, D.N. Kolbach, R.A. van Lier, F. Miedema, and L. Meyaard. 1996. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells. Eur. J. Immunol. 26:1700-1706.
30. Hedrick, S.M. 2004. The acquired immune system: a vantage from beneath. Immunity. 21:607-615.